|

Tocilizumab Clinical Trials

30 actively recruiting trials across 17 locations

▼ -2 trials since August 2026

Also known as: ACTEMRA, ACTEMRA®, Actemra, Actemra, RoActemra, Actemra, RoActemra, RO4877533 +4 more

Pipeline

Phase 1: 8Phase 2: 11Phase 3: 3Phase 4: 2Phase 1/2: 5Phase 2/3: 1

Top Sponsors

  • Hoffmann-La Roche7
  • Genentech, Inc.3
  • SCRI Development Innovations, LLC2
  • Regeneron Pharmaceuticals2
  • University of Pennsylvania1

Indications

Other7 trials

A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
Phase 2/3
A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.
Phase 2
A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
Phase 1/2
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Phase 1
Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma
Phase 2
Plan Development for Giving Teclistamab in the Outpatient Setting
Phase 4
To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
Phase 1

Birmingham, Alabama2 trials

A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

Children's Hospital of Alabama

Phase 1/2
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

University of Alabama_6th Ave

Phase 1/2

Duarte, California2 trials

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

City of Hope - Duarte

Phase 1/2
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

City of Hope

Phase 1

San Francisco, California2 trials

Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

University of California, San Francisco

Phase 2
Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis

University of California San Francisco Pediatric Rheumatology

Phase 3

Atlanta, Georgia2 trials

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

Winship Cancer Institute at Emory University

Phase 2
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers

Emory University

Phase 2

New York, New York2 trials

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

NYU Langone Health

Phase 2
Neutralizing Interleukin (IL)-6

Icahn School of Medicine at Mount Sinai

Phase 2

Philadelphia, Pennsylvania2 trials

TCR1188-ABC Cells in KRAS-mutated Cancers

University of Pennsylvania

Phase 1
Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Abramson Cancer Center of the University of Pennsylvania

Phase 1/2

Phoenix, Arizona1 trial

Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.

Phoenix Children's Hospital /ID# 253403

Phase 3

Tucson, Arizona1 trial

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Arizona Oncology Associates

Phase 2

Berkeley, California1 trial

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

Alta Bates Summit Medical Center

Phase 3

Beverly Hills, California1 trial

A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

Beverly Hills Cancer Center (BHCC)

Phase 2

La Jolla, California1 trial

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

UC San Diego Moores Cancer Center

Phase 1

Los Angeles, California1 trial

Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)

Berenson Cancer Center

Phase 4

Aurora, Colorado1 trial

ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

Children's Hospital Colorado

Phase 2

Denver, Colorado1 trial

A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma

Colorado Blood Cancer Institute

Phase 2

Boston, Massachusetts1 trial

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

Brigham And Womens Hospital

Phase 1

Rochester, Minnesota1 trial

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

Mayo Clinic Rochester

Phase 1

Pittsburgh, Pennsylvania1 trial

Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer

Allegheny Health Network Cancer Institute

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.